| Variables | Direct cost median [IQR] | Adjusted p-value |
| Hospital structure |
|
|
| YEC | 772,858 [469,021 - 1,029,745] | 0.015 |
| YCH | 601,251 [536,455 - 834,860] | |
| YGH | 1,021,823 [782,994 - 1,525,508] | |
| Health insurance |
|
|
| Not insured | 817,723 [573,388 - 1,046,305] | <0.001 |
| Insured | 324,289 [192,903 - 508,089] | |
| Type of pulmonary embolism |
|
|
| Massive | 1,102,145 [644,399 - 1,493,623] | 0.021 |
| Sub-massive | 864,150 [740,330 - 1,040,998] | |
| Low risk | 669,263 [454,458 - 939,981] | |
| Venous thromboembolic event |
|
|
| PE | 837,170 [575,196 - 1,075,720] | 0.739 |
| DVT | 540,710 [426,300 - 831,050] | |
| PE + DVT | 860,585 [758,245 - 938,359] | |
| Type of anticoagulant prescribed at discharge |
|
|
| Vitamine K antagonists | 529,728 [430,410 - 568,075] | 0.161 |
| DOA | 843,128 [635,940 - 1,056,719] | |
| DOA then AVK | 979,805 [616,501 - 1,192,708] | |
| Reoccurence |
|
|
| Present | 1,102,145 [608,066 - 1,517,235] | 0.395 |
| Absent | 757,705 [469,021 - 936,055] |